Madrigal raises $500M for NASH drug launch, discloses cyberattack
Madrigal Pharmaceuticals expects to raise $500 million from a stock and warrants sale, which it plans to use to prepare for the launch of resmetirom if it’s approved next year for an advanced liver disease called nonalcoholic steatohepatitis, or NASH.
The drug could become the first commercially available treatment for NASH.
Aside from the launch, the money could be used for R&D work, clinical trial and manufacturing costs, and notably “potential acquisitions or licensing of new technologies,” Madrigal said Thursday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.